ICUI

ICU Medical, Inc.

Fundamental data last updated:October 31, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

 


VALUATION

P/E

74.21

Market Cap ($M USD)

$3.47B

Forward P/E

12.52

PEG

0.03

PRICE TO SALES

1.61

PRICE TO BOOK

1.63

EV / EBITDA

14.39

5-Year Average P/E

Free Cash Flow Yield

2.32%

DCF Value

$-4.42

Graham Number

$59.92

Price to FCF

43.17

EV to FCF

56.27

Earnings Yield

1.35%

FCF Yield

2.32%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.87

Next Year EPS Growth Estimate

$11.09

Next Year Revenue Growth Estimate

$2.36B

Return on Equity (ROE)

2.19%

FREE CASH FLOW

Operating Margin

3.72%

Debt-to-Equity

0.66

Piotroski F-Score

5

Altman Z-Score

2.17

Return on Invested Capital (ROIC)

2.29%

Current Ratio

2.30

Quick Ratio

1.13

Net Debt to EBITDA

3.35

Interest Coverage

1.57

Gross Profit margin

36.36%

FCF PER SHARE

$3.25

REVENUE PER SHARE

$87.08

Gainseekers Quantitative Analysis

Summary

ICU Medical, Inc. appears to be a perplexing case of valuation versus potential. The stock’s snapshot price traded significantly below its DCF value, suggesting a market mispricing. However, a sky-high P/E ratio of 67.56 contrasts sharply with a more reasonable forward P/E of 11.40, indicating expectations of substantial earnings growth. The Altman Z-score of 2.08 raises caution about financial distress, while the earnings yield of 1.48% is underwhelming. The market seems to be pricing in a turnaround, but the financial health signals a mixed bag.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, ICU Medical is strategically positioned to leverage AI and tech advancements. The healthcare sector's increasing reliance on data analytics and automation could enhance operational efficiencies. However, the company's adaptability will depend on its ability to integrate these technologies into its existing product lines.

The Bull Case

For the discerning GARP investor, ICU Medical presents a compelling opportunity. With a forward PEG ratio of just 0.02, the stock is priced for growth at a bargain. The ROIC of 2.29% and a Piotroski F-Score of 5 suggest moderate capital efficiency and operational health. Despite a modest operating margin of 3.72%, the company's ability to generate free cash flow, albeit with a yield of 2.54%, indicates potential for reinvestment and growth.

The Bear Case

Yet, the bear case cannot be ignored. The Price to FCF ratio of 39.30 and an EV to FCF of 51.65 highlight a concerning overvaluation relative to cash flow generation. The company's net debt to EBITDA ratio of 3.16 and an interest coverage of just 1.57 signal financial strain. Additionally, trading close to its 52-week high, the stock may be technically overextended, posing risks for new investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$164.00

Institutional Ownership %

1-Year Beta

0.74

Insider Buying % (6 Mo)

Distance to 52-Week High

15.42%

Distance to 52-Week Low

22.95%

EARNINGS SURPRISE %

10.67%

50-DAY SMA

$125.65

200-DAY SMA

$133.74

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.